Differences in guidelines for multiple sclerosis (MS) management created confusion during the onset of the pandemic. According to Joseph R. Berger, MD, a professor of Neurology, “we really had no hard data on how the disease itself would be affected by MS, and how MS would be affected by COVID. And more importantly, how people on disease-modifying therapies (DMTs) would respond to COVID, and whether it would increase the morbidity and mortality of COVID.” Berger and colleagues published a review of the current state of knowledge regarding the effect of MS DMTs on COVID-19 illness.
Comments